Bipartisan Support For Comparative Efficacy Policy Likely To Grow - McClellan
This article was originally published in The Pink Sheet Daily
Executive Summary
Increasing interest in demonstrating safety, efficacy and value of medications will drive development of policies around comparative evidence, the former FDA head predicts.
You may also be interested in...
Senate Blocks Medicare Drug Price Negotiation Bill From Floor Vote
Sen. Baucus’ effort to simply strike the non-interference clause, rather than requiring negotiations, did not garner enough support to force a vote.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.